Olaparib for BRCA-mutated advanced ovarian cancer

被引：2
|
作者：
de Lartigue, Jane
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2015年 / 13卷 / 06期
关键词：
D O I：
10.12788/jcso.0138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：206 / 208
页数：3
相关论文
共 50 条
  • [31] Doubling Down on BRCA-Mutated Cancer
    Hendrickson, Andrea E. Wahner
    Kaufmann, Scott H.
    Swisher, Elizabeth M.
    [J]. TRENDS IN CANCER, 2017, 3 (11): : 743 - 744
  • [32] Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
    Velev, Maud
    Puszkiel, Alicja
    Blanchet, Benoit
    de Percin, Sixtine
    Delanoy, Nicolas
    Medioni, Jacques
    Gervais, Claire
    Balakirouchenane, David
    Khoudour, Nihel
    Pautier, Patricia
    Leary, Alexandra
    Ajgal, Zahra
    Hirsch, Laure
    Goldwasser, Francois
    Alexandre, Jerome
    Beinse, Guillaume
    [J]. PHARMACEUTICALS, 2021, 14 (08)
  • [33] Subtypes in BRCA-mutated breast cancer
    Sonderstrup, Ida Marie H.
    Jensen, Maj-Britt R.
    Ejlertsen, Bent
    Eriksen, Jens O.
    Gerdes, Anne-Marie
    Kruse, Torben A.
    Larsen, Martin J.
    Thomassen, Mads
    Laenkholm, Anne-Vibeke
    [J]. HUMAN PATHOLOGY, 2019, 84 : 192 - 201
  • [34] Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer.
    Zettler, Christie
    De Silva, Dilanka
    Blinder, Victoria Susana
    Robson, Mark E.
    Elkin, Elena B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: US retrospective cohort study.
    Eskander, Ramez Nassef
    Alam, Naufil
    Long, Grainne H.
    Ozgoren, Ozan
    Ambler, Will
    Volpe, Stephanie
    Moore, Kathleen N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] PARP inhibition in BRCA-mutated breast and ovarian cancers
    Chan, Stephen L.
    Mok, Tony
    [J]. LANCET, 2010, 376 (9737): : 211 - 213
  • [37] Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Li, Na
    Zheng, Huanrui
    Huang, Yanlei
    Zheng, Bin
    Cai, Hongfu
    Liu, Maobai
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] EFFICACY AND SAFETY OF MAINTENANCE OLAPARIB BY PATIENT AGE IN NON-GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER IN OPINION
    Skof, E.
    Bjurberg, M.
    Rubio Perez, M. J.
    Davidson, D.
    Blakeley, C.
    Bennett, J.
    Poveda, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A202 - A203
  • [39] Fertility preservation in BRCA-mutated breast cancer patients
    Lambertini, Matteo
    Del Mastro, Lucia
    [J]. BREAST CANCER MANAGEMENT, 2016, 5 (02) : 61 - 68
  • [40] NEW TREATMENT FOR BRCA-MUTATED METASTATIC BREAST CANCER
    Aschenbrenner, Diane S.
    [J]. AMERICAN JOURNAL OF NURSING, 2018, 118 (05) : 21 - 23
12345